The MPO-463G>A polymorphism and lung cancer risk: a meta-analysis based on 22 case-control studies

Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO-463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO-...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-06, Vol.8 (6), p.e65778
Main Authors: Yang, Jun-Ping, Wang, Wen-Bo, Yang, Xiao-Xi, Yang, Lei, Ren, Li, Zhou, Fu-Xiang, Hu, Liu, He, Wei, Li, Bai-Yu, Zhu, Yan, Jiang, Huan-Gang, Zhou, Yun-Feng
Format: Article
Language:English
Subjects:
Bias
Biology
Biomarkers
Cancer
Carcinogenesis
Carcinogens
Case-Control Studies
Clinical trials
Confidence intervals
Deoxyribonucleic acid
DNA
DNA methylation
Epidemiology
Gene Frequency
Genes
Genetic Association Studies
Genetic Predisposition to Disease
Health risks
Hospitals
Humans
Lung cancer
Lung diseases
Lung Neoplasms - genetics
Medical ethics
Medicine
Meta-analysis
Minority & ethnic groups
Models, Genetic
Mutagenesis
Oncology
Oxygen
Peroxidase
Peroxidase - genetics
Polymorphism
Polymorphism, Single Nucleotide
Population studies
Radiation therapy
Reactive oxygen species
Risk analysis
Risk Factors
Smoking
Studies
Tobacco smoke
Transcription
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myeloperoxidase (MPO) is an endogenous oxidant enzyme that produces reactive oxygen species (ROS) and may be involved in lung carcinogenesis. The MPO-463G>A polymorphism influences MPO transcription and has been associated with lung cancer susceptibility. However, the association between the MPO-463G>A polymorphism and lung cancer risk remains controversial. To investigate the effect of this polymorphism on lung cancer susceptibility, we performed a meta-analysis based on 22 published case-control studies including 7,520 patients with lung cancer and 8,600 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Overall, there was no evidence for significant association between MPO-463G>A polymorphism and lung cancer susceptibility (for AA versus GG: OR = 0.91, 95%CI = 0.67-1.24; for GA versus GG: OR = 0.87, 95% CI = 0.78-0.98; for AA/GA versus GG: OR = 0.90, 95% CI = 0.80-1.01; for AA versus OR = 0.96, 95% CI = 0.72-1.28). In the stratified analyses by ethnicity, source of controls and smoking status, we also did not find any significant association between them. In summary, this meta-analysis suggests MPO-463G>A polymorphism may not be a risk factor for developing lung cancer. However, further prospective well-designed population-based studies with larger sample size are expected to validate the results.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0065778